-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 25, 2021, AstraZeneca announced that the blockbuster PD-L1 inhibitor durvalumab (durvalumab, English trade name: Imfinzi) was combined with chemotherapy for the first-line treatment of advanced biliary tract cancer ( BTC) patients reached the primary endpoint in a phase 3 clinical trial
.
Compared with chemotherapy alone, the duvalimab combination provides patients with a statistically significant and clinically significant overall survival (OS) benefit
In addition, the combination therapy also significantly improved the patient's progression-free survival (PFS) and overall response rate
.
In terms of safety, the combination therapy was well tolerated, and its safety characteristics were similar to those of the control drug group, and did not increase the withdrawal rate due to adverse events
Advanced biliary tract cancer is a group of rare and aggressive gastrointestinal (GI) cancers that usually occur in the bile duct and gallbladder.
There are approximately 210,000 newly diagnosed patients worldwide each year
.
The early stage of the disease is often asymptomatic, so most new cases are already in the late stage when they are diagnosed, and treatment options are limited at this time
About 72% of patients with intrahepatic biliary tract cancer express PD-L1
.
Duvalvumab is a humanized monoclonal antibody that can bind to PD-L1 protein, block its binding to PD-1 and CD80, fight tumor immune escape, and relieve the suppression of anti-cancer immune response
Reference materials:
[1] IMFINZI plus chemotherapy significantly improved overall survival in 1st-line advanced biliary tract cancer in TOPAZ-1 Phase III trial at interim analysis.
(The original text has been deleted)
